Reuters logo
4 years ago
Actelion close to sealing Ceptaris deal as US approves drug
August 26, 2013 / 5:31 AM / 4 years ago

Actelion close to sealing Ceptaris deal as US approves drug

ZURICH, Aug 26 (Reuters) - Swiss biotech firm Actelion said an important condition for its acquisition of privately-held Ceptaris was met with Ceptaris gaining U.S. approval for its Valchlor gel.

The companies are now completing further closing conditions before the acquisition is concluded, Actelion said in a statement on Monday.

The U.S. health regulator FDA has approved Ceptaris Therapeutics' topical drug for treatment of a rare form of non-Hodgkin's lymphoma, Actelion said.

The Allschwil-based company said in July it already paid Ceptaris $25 million and will pay another $225 million when the deal closes.

Reporting by Alice Baghdjian

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below